| 000 | 07274cam a2201369 4500500 | ||
|---|---|---|---|
| 005 | 20250117194437.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aEddehbi, Fatima-Ezzohra _eauthor |
| 700 | 1 | 0 |
_a Salami, Abdelmouine _eauthor |
| 700 | 1 | 0 |
_a Idam, Fayssal _eauthor |
| 700 | 1 | 0 |
_a Hazime, Raja _eauthor |
| 700 | 1 | 0 |
_a Admou, Brahim _eauthor |
| 245 | 0 | 0 | _aAssociations cliniques des anticorps anti-Jo1 chez une population marocaine |
| 260 | _c2024. | ||
| 500 | _a1 | ||
| 520 | _aAnti-Jo1 antibodies are usually known markers of myositis. However, they can be associated with different pathologies. We aimed to determine the immuno-clinical characteristics of patients with positive anti-Jo1. We enrolled 31 anti-Jo1 positive patients, selected from 10429 cases tested for antinuclear antibodies (ANA) by indirect immunofluorescence. The anti-Jo1 identification was motivated by the ANA pattern or the clinical data of patients. The average age of patients was 36.9 ± 10 years (F/M sex ratio: 3.4). The overall prevalence of anti-Jo1 was 0.3% among all ANA-tested cases. The ANA pattern associated with the presence of anti-Jo1 was heterogeneous with ANA negative in 38.7 % of cases. They were associated with different autoantibody specificities in 64.5 % of cases and were alone in 35.5% of cases. When confronted with clinical data, anti-Jo1 positivity was associated with autoimmune (77,4%) and non-autoimmune (22,6%) clinical conditions. Our study shows a low overall prevalence of anti-Jo1. These antibodies must be systematically tested for in the context of myositis even if ANA is negative. Nevertheless, their positivity in other systemic or even non-autoimmune diseases requires further studies to better understand their clinical significance. | ||
| 520 | _aLes anticorps anti-Jo1 sont habituellement des marqueurs connus des myosites, ils peuvent cependant s’associer à différentes pathologies. Notre objectif était de déterminer les caractéristiques immuno-cliniques des patients positifs en anti-Jo1. Nous avons colligé 31 patients positifs en anti-Jo1, sélectionnés à partir de 10429 cas testés pour anticorps antinucléaires (AAN) par immunofluorescence indirecte. L’identification des anti-Jo1 était guidée par l’aspect des AAN ou les données cliniques des patients. La moyenne d’âge des patients était de 36.9 ± 10 ans (sexe ratio F/M : 3,4). La prévalence globale des anti-Jo1 était de 0,3 % parmi l’ensemble des cas testés en AAN. L’aspect des AAN associé à la présence des anti-Jo1 était hétérogène, avec AAN négatifs dans 38,7 % des cas. Ils étaient associés à différentes spécificités auto-anticorps dans 64,5 % des cas et isolés dans 35,5 % des cas. Confrontée aux données cliniques, leur positivité était associée à des pathologies auto-immunes (77,4 %) et non auto-immunes (22,6 %). Notre étude montre une prévalence globale faible des anti-Jo1. Leur recherche doit être systématique devant la suspicion de myosite même en absence d’AAN. Néanmoins, leur existence au cours d’autres maladies de système voire non auto-immunes, justifie des études complémentaires en vue de mieux comprendre leur signification clinique. | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _asignification clinique | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanticorps anti-Jo1 | ||
| 690 | _aanticorps anti-nucléaires | ||
| 690 | _asignification clinique | ||
| 690 | _aimmunofluorescence indirecte | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aclinical significance | ||
| 690 | _aanti-Jo1 antibodies | ||
| 690 | _aindirect immunofluorescence | ||
| 690 | _aanti-nuclear antibodies | ||
| 690 | _aclinical significance | ||
| 786 | 0 | _nAnnales de Biologie Clinique | 82 | 5 | 2024-12-04 | p. 555-562 | 0003-3898 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-annales-de-biologie-clinique-2024-5-page-555?lang=fr&redirect-ssocas=7080 |
| 999 |
_c277279 _d277279 |
||